Smith & Nephew - SNN Stock Forecast, Price & News

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Analysts Set New Price Targets

SNN has been the subject of a number of research analyst reports. Canaccord Genuity Group downgraded shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Thursday, July 28th. Canaccord Genuity Group downgraded shares of Smith & Nephew from a "buy" rating to a "hold" rating in a report on Thursday, July 28th. Barclays dropped their price objective on shares of Smith & Nephew from GBX 1,650 ($19.94) to GBX 1,630 ($19.70) in a research note on Tuesday, July 5th. StockNews.com cut shares of Smith & Nephew from a "strong-buy" rating to a "buy" rating in a report on Friday, July 8th. Finally, UBS Group dropped their price target on shares of Smith & Nephew from GBX 1,190 ($14.38) to GBX 1,116 ($13.48) in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Smith & Nephew presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,396.00.

Smith & Nephew Price Performance

Shares of NYSE:SNN opened at $26.19 on Wednesday. Smith & Nephew has a 52 week low of $24.80 and a 52 week high of $39.19. The company's 50-day moving average price is $27.66 and its 200 day moving average price is $30.82. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.78 and a quick ratio of 0.84.

Smith & Nephew Dividend Announcement

The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, October 26th. Shareholders of record on Friday, September 30th will be given a $0.288 dividend. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, September 29th.